

### **SUPPLEMENTAL EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.
2. During a telephone conversation with Sally Teng on July 11, 2008, this supplemental examiner amendment was made to correct typographical/grammatical mistakes in the examiner amendment mailed 6/2/08.
3. Authorization for this examiner's amendment was given in a telephone interview with Sally P. Teng on May 15, 2008.

The application has been amended as follows:

In claim 93, --synaptic vesicle protein 2--was inserted between "an" and "SV2" in line 2, and the "SV2" in the line 2 was changed to "(SV2)".

In claim 93, the recitation of "an LBS" in line 6 was changed to "a LBS".

In claim 93, the recitation of "a SV2" in line 6 was changed to "an SV2".

In claim 139, the recitation of "an LBS" in line 6 was changed to "a LBS".

In claim 139, "~~SV2B~~" in line 4 was changed to "SV2C".

In claim 139, the recitation of "a SV2" in line 6 was changed to "an SV2".

In claim 156, "~~SV2B~~" in line 4 was changed to "SV2C".

In claim 175, --the amino acid sequence of-- was inserted following "SEQ ID NO:2" and "SEQ ID NO:6" .

In claim 180, --the amino acid sequence of-- was inserted following "SEQ ID NO:2" and "SEQ ID NO:6"

In claim 186, --the amino acid sequence of-- was inserted following "SEQ ID NO:2" and "SEQ ID NO:6"

Claims 93-95, 97-101, 139-141, 144-154, 156, 174-183, and 185-189 were renumbered as claims 1-38.

The title of the instant invention was changed to "Methods for identifying agents that bind a levetiracetam binding site (LBS) or compete with LEV binding to a LBS of a synaptic vesicle protein 2 (SV2)."

4. During a telephone conversation with Sally Teng on May 16, 2008, the recitation of "a SV2" in the claims would be changed to "an SV2" to be consistent with the disclosure in the specification. Thus, "a SV2" in line 6 of claims 93 and 139 was changed to "an SV2"

5. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1649

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chang-Yu Wang whose telephone number is 571-272-4521. The examiner can normally be reached on Monday through Thursday and every other Friday 8:30am to 5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Stucker, can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Christine J Saoud/  
Primary Examiner, Art Unit 1647

/CYW/  
Chang-Yu Wang, Ph.D.  
July 11, 2008